

DRUG PROFILE**UPDATE ON USE OF THE NEWER ANTISEIZURE MEDICATIONS IN CHILDREN AND ADOLESCENTS**

***Jeerson C Unni**
****Mohammed Kunju PA**

Abstract: Administration of antiseizure medications is the first-line treatment for epilepsy, one of the most common neurological diseases. There were very few medications for treating children with seizure disorder till two and a half decades ago. Though some newer drugs have been approved, there continues to be an unmet need for efficacious newer antiseizure medications with good safety profile. Research for an ideal antiseizure medication is the need of the hour. This article attempts to highlight the travails of pediatric neurologists in the pharmaco-management options for difficult to treat seizure disorders.

Keywords: Newer antiseizure medications, Intractable seizures, Children, Adolescents.

Points to Remember

- *Most of the newer antiseizure medications are used for controlling difficult (to control) seizures.*
- *The most useful advantage is their safety profile.*
- *As per Nice Guidelines lamotrigine and levetiracetam are first line monotherapy for focal seizures.*

References

1. Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: Impact and future perspectives. *Lancet Neurol* 2020; 19: 544-556. doi: 10.1016/s1474-4422(20)30035-1.
2. Sills GJ. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. *Ther Adv Neurol Disord*. 2023 Aug 30; 16:17562864231191000. doi: 10.1177/17562864231191000. PMID: 37655228; PMCID: PMC10467199.
3. Wirrell E, Wong-Kisiel L, Mandrekar J, Nickels K. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: A retrospective, population-based study. *Epilepsia*. 2012 Sep;53(9):1563-9. doi: 10.1111/j.1528-1167.2012.03562.
4. French JA. Refractory Epilepsy: Clinical Overview. *Epilepsia* 2007; 48(Suppl 1): 3-7. doi: 10.1111/j.1528-1167.2007.00992.
5. Aneja S, Sharma S. Newer Anti-epileptic Drugs. *Indian Pediatr* 2013; 50: 1033-1040. doi: 10.1007/s13312-013-0284-9.
6. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. *Brain and Development* 2001; 23(5): 277-283. doi: 10.1016/s0387-7604(01)00230-3.
7. White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, et al. Discontinuation of levetiracetam because of behavioral side effects: a casecontrol study. *Neurology* 2003;61(9):12181221. doi: 10.1212/01.wnl.0000091865.46063.67.
8. Feyissa AM. Brivaracetam in the treatment of epilepsy: A review of clinical trial data. *Neuropsychiatr Dis Treat*. 2019; 15:2587-2600. doi: 10.2147/NDT.S143548.

* Editor-in-Chief, IAP Drug formulatory, Senior Consultant, Aster Medcity, Kochi
email: jeerson1955@gmail.com

** Professor and Senior Consultant, KIMS Health, Tirvandrum.

9. Li KY, Hsu CY, Yang YH. A review of cognitive and behavioral outcomes of Brivaracetam. *Kaohsiung J Med Sci.* 2023 Feb;39(2):104-114. doi: 10.1002/kjm2.12648.
10. BNF for Children 2019-2020. BMJ Group Tavistock Square, London, WC1H 9JP, UK and Pharmaceutical Press, Royal Pharmaceutical Society. 66-68 East Smithfield, London E1W1AW, UK.
11. Hibi S, Ueno K, Nagato S, Kawano K, Ito K, Norimine Y, et al. Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzotrile (perampnel): a novel, noncompetitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. *MedChem* 2012; 55(23): 10584-10600. doi: 10.1021/jm301268u.
12. Greene IP, Lee EY, Prow N, Ngwang B, Griffin DE. Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. *Proc Natl Acad Sci U S A* 2008; 105(9): 3575-3580. doi: 10.1073/pnas.0712390105.
13. IAP Drug Formulary 2024 with Recommendations for drug treatment for pediatric illness, Eds. Jeelson C Unni, Pallab Chatterjee. 6th edition. Publication of Indian Academy of Pediatrics, Project of IAP CMIC. 2024. Pixel Studio, Kochi. S India.
14. Fisher JL. The effects of stiripentol on GABA(A) receptors. *Epilepsia* 2011; 52 Suppl 2(0 2): 76-78. doi: 10.1111/j.1528-1167.2011.03008. x.
15. Tran A, Rey E, Pons G, Rouseau M, d'Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants. *ClinPharmacolTher* 1997; 62:490-504.
16. Buck ML, Goodkin HP. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome. *Ann Pharmacother.* 2019 Nov;53(11):1136-1144. doi: 10.1177/1060028019856008. Epub 2019 Jun 6.
17. Kadian R, Kumar A. Zonisamide. [Updated 2023 May 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507903/> Accessed on 1/02/ 2024.
18. Aneja S, Sharma S. Newer anti-epileptic drugs. *Indian Pediatr* 2013; 50(11): 1033-1040.
19. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. *Epilepsy Res* 1998; 29(2): 109-14.
20. Wilfong AA, Willmore LJ. Zonisamide - a review of experience and use in partial seizures. *Neuropsychiatr Dis Treat.* 2006 Sep;2(3): 269-80. doi: 10.2147/nedt.2006.2.3.269.
21. Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. *Drugs R D.* 2017 Sep;17(3):329-339. doi: 10.1007/s40268-017-0197-5.
22. Leslie TK, Brückner L, Chawla S, Brackenbury WJ. FrontInhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na 1.5 Channels. *Pharmacol* 2020 Oct 2; 11:555047. doi: 10.3389/fphar.2020.555047. eCollection 2020.
23. Ben-Menachem E. Eslicarbazepine acetate: a well-kept secret? *Epilepsy Curr* 2010; 10(1): 7-8.
24. Lai MC, Wu SN, Huang CW. Rufinamide, a Triazole-Derived Antiepileptic Drug, Stimulates Ca²⁺-Activated K⁺ Currents While Inhibiting Voltage-Gated Na⁺ Currents. *Int J MolSci* 2022; 23(22): 13677. doi: 10.3390/ijms232213677.
25. Hsieh DT, Thiele EA. Efficacy and safety of rufinamide in pediatric epilepsy. *Ther Adv NeurolDisord.* 2013 May;6(3):189-98. doi: 10.1177/1756285613481083.
26. Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. *Epilepsia.* 2009 Aug;50(8):1899-909. doi: 10.1111/j.1528-1167.2009.02160. x. Epub 2009 Jun 1.
27. Coppola G. Update on rufinamide in childhood epilepsy. *Neuropsychiatr Dis Treat* 2011; 7: 399-407.
28. Buck ML, Goodkin HP. Use of lacosamide in children with refractory epilepsy. *J PediatrPharmacol Ther.* 2012 Jul;17(3):211-9. doi: 10.5863/1551-6776-17.3.211.
29. Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. *Ther Clin Risk Manag* 2019; 15: 951-955.
30. Mayo Clin, Everolimus (Oral Route). Drugs and supplements. <https://www.mayoclinic.org/drugs-supplements/everolimus-oral-route/side-effects/drg-20072842>. Accessed on 1/3/24.
31. Owen RT. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. *Drugs Today (Barc)* 2010; 46(11): 815-822.
32. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE. Retigabine: chemical synthesis to clinical application. *CNS Drug Rev* 2005; 11(1): 1-20. doi: 10.1111/j.1527-3458.2005.tb00033. x.
33. Ciliberto MA, Weisenberg JL, Wong M. Clinical utility, safety and tolerability of ezogabine (retigabine) in the treatment of epilepsy. *Drug Healthc Patient Saf* 2012; 4: 81-86.

34. Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. *Semin PediatrNeurol* 2010; 17: 214-223.
35. Walleigh DJ, Legido A, Valencia I. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. *PediatrNeurol* 2013; 49: 368-369.
36. Reddy DS. Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic. *J PharmacolExp Ther.* 2024; 388(2):273-300. doi: 10.1124/jpet.123.001816.
37. Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. *Epilepsy Res* 2000; 42: 133-139.
38. Olson HE, Amin S, Bahi-Buisson N, Devinsky O, Marsh ED, Pestana-Knight E, et al. Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up. *Epilepsia* 2024; 65(1): 37-45. doi: 10.1111/epi.17826.
39. Silvestro S, Schepici G, Bramanti P, Mazzon E. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. *Molecules* 2020; 25(21) :5186. doi: 10.3390/molecules25215186.
40. Moreira GA, MoraesNeto R, Ribeiro RG, Crippa ACS. Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature. *Rev Paul Pediatr* 2022;41:e2021197. doi: 10.1590/1984-0462/2023/41/2021197.
41. Samanta D. Fenfluramine: A Review of Pharmacology, Clinical Efficacy and Safety in Epilepsy. *Children (Basel)* 2022; 9(8): 1159. doi: 10.3390/children9081159.
42. NICE guideline [NG217] Epilepsies in children, young people and adults Published: 27 April 2022. <https://www.nice.org.uk/guidance/ng217>. Accessed on 10.3.27.
43. Roberti R, Di Gennaro G, Anzellotti F, Arnaldi D, Belcastro V, Beretta S, et al. COMPARE Study Group; Russo E. A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study. *Epilepsia.* 2024;65(2):456-472. doi: 10.1111/epi.17843.